Drug delivery: Enabling technology for drug discovery and development. iPRECIO® Micro Infusion Pump: programmable, refillable, and implantable

Frontiers in Pharmacology

Volumn JUL, Issue , 2011, Pages

  Tan, Tsung ^a   Watts, Stephanie W ^b   Davis, Robert Patrick ^b  

^a Primetech Corporation   (Japan)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Dose response; Drug delivery; Implantable pump; Mini pump; Osmotic pumps; Preclinical; Quantitative pharmacol ogy; Telemetry

Indexed keywords

ANGIOTENSIN II; CYANOCOBALAMIN; DEOXYCORTICOSTERONE ACETATE; DOBUTAMINE; DRUG VEHICLE; LOSARTAN; OLANZAPINE; SEROTONIN; VALSARTAN; VERAPAMIL;

ARTICLE; BLOOD BRAIN BARRIER; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG BLOOD LEVEL; DRUG DELIVERY DEVICE; DRUG DEPENDENCE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG INFUSION; DRUG MEGADOSE; DRUG TARGETING; EUROPE; GOLD STANDARD; IMPLANTABLE PUMP; INFUSION PUMP; INFUSION RATE; INFUSION SYSTEM; JAPAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRODUCT DEVELOPMENT; PROGRAMMABLE PUMP; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REFILLABLE PUMP; SENSITIVITY ANALYSIS; TELEMETRY; TREATMENT OUTCOME; UNITED STATES;

EID: 84858251823     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00044     Document Type: Article

References (40)

1. Abe, C., Tanaka, K., Iwata, C., and Morita, H. (2010). Vestibularmediated increase in central serotonin plays an important role in hyper gravity-induced hypophagia in rats. J. Appl. Physiol. 109, 1635-1643.
2. Abe, C., Tashiro, T., Tanaka, K., Ogihara, R., and Morita, H. (2009). A novel type of implantable and programmable infusion pump for small laboratory animals. J. Pharmacol. Toxicol. Methods 59, 7-12.
3. Anonymous. (2001). Refining procedures for the administration of substances. Lab. Anim. 35, 1-41.
4. Anonymous. (2011a). Alzet ®. Available at: http://www.alzet.com/May 9th 2011 12:58
5. Anonymous. (2011b). iPRECIO®. Available at: http://www.iprecio. com/May 9th 13:33
6. Anonymous. (2011c). To our knowledge (at Primetech). Data and application information have not always been shared freely by users of iPRECIO® pumps due to confidentiality. Available at: http://www.iprecio.com/application/ index.html
7. Coles, D. I., Warr, A., and Mead, A. (2010). Characterization of pentobarbital physical dependence and withdrawal in rats. J. Pharmacol. Toxicol. Methods 62, e9.
8. Davis, P., Fink, G., Seitz, B., and Watts, W. (2010). Serotonin infusion via the iPrecio® micro infusion pump results in repeated reductions in blood pressure in the normotensive Sprague Dawley rat. FASEB J. 24, lb551.
9. Douglas, G., Jones, H., Edgington, A., Saunders, K., Neil Morgan, S, Pullen, N., and Parenty, G. (2011) GPR54 Agonists a Way Forward for Downregulation of the GnRH Pathway? 10th International Symposium on GnRH, Salzburg. Geneva: Kenes International.
10. Gabrielsson, J., Green, A. R., and Van der Graaf, P. H. (2010). Optimizing in vivo pharmacology studies-practical PKPD considerations. J. Pharmacol. Toxicol. Methods 61, 146-156.
11. Gad, S. C., Cassidy, C. D., Aubert, N., Spainhour,B.,and Robbe,H. (2006). Non clinical vehicle use in studies by multiple routes in multiple species. Int. J. Toxicol. 25, 499-521.
12. Gizzi,J.,Baird,T.,O'Donohue,K.,Yoder, J., Grenwis, J., and Bogie, H. (2011a). Optimization of a fully implantable small animal infusion model involving multi-pressure data collection. FASEB J. 25, 11264.
13. Gizzi,J.,Baird,T.,O'Donohue,K.,Yoder, J., Grenwis, J., and Bogie, H. (2011b). Michigan State University, Personal communication with the authors.
14. Kenakin, T. (2009). "Statistics and experimental design," in Pharmacology Primer, 2nd Edn (San Diego, CA: Academic Press).
15. Khan, Z., Pillay, V., Choonara, Y. E., and du Toit, L. C. (2009). Drug delivery technologies for chronotherapeutic applications. Pharm. Dev. Technol. 14, 602-612.
16. Korfmacher, W. A. (2009). Advances in the integration of drug metabolism into the lead optimization paradigm. Mini Rev. Med. Chem. 9, 703-716.
17. Kwong, E., Higgins, J., and Templeton, A. C. (2011). Strategies for bringing drug delivery tools into discovery. Int. J. Pharm. 412, 1-7.
18. Lee, Y. C., Zocharski, P. D., and Samas, B. (2003). An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 252, 111-119.
19. Li, P., and Zhao, L. (2007). Developing early formulations: practice and perspective. Int. J. Pharm. 341, 1-19
20. Martel, E. (2011). "Refined rat pharmacology studies with infusion using implantable pumps," in DSI User Group Meeting, Paris.
21. Mass, J., Kamm, W., and Hauck, G. (2007). An integrated early formulation strategy-from hit evaluation to preclinical candidate profiling. Eur. J. Pharm. Biopharm. 66, 1-10.
22. Matsuoka, E., Miyazaki, M., Iwanaga, K., and Kakemi, M. (2007) "Assessment of pharmacokineticpharmacodynamic relationship of vitamin B12 in the treatment of somnipathy in rats," in 14th Annual Meeting of Japanese Society for Chronobiology, Tokyo.
23. Neervannan, S. (2006). Preclinical formulations for discovery and toxicology: physiochemical challenges. Expert Opin. Drug Metab. Toxicol. 2, 715-731.
24. Osborn, J., presenter and Fink, G., discussant. (2011). "Implantable infusion pumps for chronic rodent studies," in Workshop: Rodent Instrumentation Workshop M. Knuepfer, Experimental Biology 2011, Washington, DC.
25. Palucki, M., Higgins, J., Kwong, E., and Templeton, A. (2010). Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. J. Med. Chem. 53, 5897-5905.
26. Rosen, H., and Abribat, T. (2005). The rise and rise of drug deliv-ery. Nat. Rev. Drug Discov.4, 381-385.
27. Schnell, C., and Ferrat, T. (2011) "Use of novel programmable pump for intracranial administration in an orthotopic glioblastoma tumor model in rats," in DSI User Group Meeting, Paris.
28. Shobo, M., Yamada, H., Koakutsu, A., Hamada, N., Fujii, M, Harada, K., Ni, K., and Matsuoka, N. (2011). Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats. Life Sci. 88, 761-765.
29. Shobo, M., Yamada, H., Koakutsu, A., Harada, K., Ni, K., and Matsuoka, N. (2010). "Effect of long-term electrical infusion of olanzapine on fat weight in rats: a novel method for administration of biologically and/or chemically fragile compounds," in The 83rd Annual Meeting of the Japanese Pharmacological Society, Osaka.
30. Strickley, R. G. (2004). Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201-230.
31. Strickley, R.G. (2008). "Formulation in drug discovery," in Annual Reports in Medicinal Chemistry, Vol. 43, ed J. E. Macor (London: Academic Press), 419-451.
32. Tan, T., and Tsuru, T. (2009) Infusion Pumps for Small Laboratory Animals. Available at: ALN Magazine May/June http://www.alnmag. com/article/infusion-pumps-smalllaboratoryanimals
33. Van Der Graaf, P. H., and Gabrielsson, J. (2009). Pharmacokineticpharmacodynamic reasoning in drug discovery and early devel-opment. Future Med. Chem.1, 1371-1374.
34. Walker, D. K. (2004). The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drugdevelopment. Br. J. Clin. Pharmacol. 58, 601-608.
35. Wehling,M. (2009). Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug Discov. 8, 541-546.
36. Wendler, A., and Wehling, M. (2010). The translatability of animal models for clinical development: biomarkers and disease models. Curr. Opin. Pharmacol. 10, 601-606.
37. Wittenburg, L. A., and Gustafson, D. L. (2011). Optimizing preclinical study design in oncology research. Chem. Biol. Interact. 190, 73-78.
38. Yamato, M., Okuyama, K., Jin, G. H., Eguchi, A., Watanabe, Y., and Kataoka,Y. (2010)." Endogenous IL1β and IL-1 receptor antagonist in the brain are involved in poly I: c-induced immunological fatigue," in The 33rd Annual Meeting of the Japan Neuroscience Society,Kobe.
39. Yoshinori, T. (2011) "Extracellular protein phosphorylation promotes functional recovery from experimental spinal cord injury," in The 6th International Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects-Development of Novel Therapy to Specific Disease in organ,Kyoto.
40. Zaretskya, D. V., Zaretskaiaa, M. V., Rusyniaka, D. E., and DiMiccob, J. A. (2011). Stress-free microinjections in conscious rats. J. Neurosci. Methods 199, 199-207.